MX2011009807A - Compuestos. - Google Patents

Compuestos.

Info

Publication number
MX2011009807A
MX2011009807A MX2011009807A MX2011009807A MX2011009807A MX 2011009807 A MX2011009807 A MX 2011009807A MX 2011009807 A MX2011009807 A MX 2011009807A MX 2011009807 A MX2011009807 A MX 2011009807A MX 2011009807 A MX2011009807 A MX 2011009807A
Authority
MX
Mexico
Prior art keywords
aryl
heterocycloalkyl
heteroaryl
cycloalkyl
alkyl
Prior art date
Application number
MX2011009807A
Other languages
English (en)
Inventor
Edward Giles Mciver
Ela Smiljanic
Denise Jamilla Harding
Joanne Hough
Original Assignee
Medical Res Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0904746A external-priority patent/GB0904746D0/en
Priority claimed from GB0912238A external-priority patent/GB0912238D0/en
Priority claimed from GBGB1001418.1A external-priority patent/GB201001418D0/en
Application filed by Medical Res Council Technology filed Critical Medical Res Council Technology
Publication of MX2011009807A publication Critical patent/MX2011009807A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs

Abstract

Un compuesto de la fórmula (I), o una sal o éster farmacéuticamente aceptable del mismo, en donde R1 se selecciona de: arilo; heteroarilo;-NHR3 aril-C4-7- heterocicloalquilo fusionado; -CONR4R5 -NHCOR6 -C3-7- cicloalquilo; -O-C3-7-cicloalquilo; -NR3R6 y -C1-6 alquilo opcionalmente sustituido; en donde el arilo, heteroarilo, aril-C4-7-heterocicloa lquilo fusionado y C4-7-heterocicloalquilo cada uno son sustituidos opcionalmente; R2 se selecciona de hidrógeno, arilo, C1-6-alquilo, C2-6-alquenilo, C3-7-cicloalquilo, heteroarilo, C4-7 heterocicloalquilo y halógeno, en donde el C1-6-alquilo, C2-6-alquenilo, arilo, heteroarilo y C4-7-heterocicloalquilo cada uno son sustituidos opcionalmente. Los aspectos adicionales se refieren a composiciones farmacéuticas, usos terapéuticos y procesos para preparar los compuestos de la fórmula (I).
MX2011009807A 2009-03-19 2010-03-19 Compuestos. MX2011009807A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0904746A GB0904746D0 (en) 2009-03-19 2009-03-19 Compounds
US16202409P 2009-03-20 2009-03-20
GB0912238A GB0912238D0 (en) 2009-07-14 2009-07-14 Compounds
GBGB1001418.1A GB201001418D0 (en) 2010-01-28 2010-01-28 Compounds
PCT/GB2010/000498 WO2010106333A1 (en) 2009-03-19 2010-03-19 Compounds

Publications (1)

Publication Number Publication Date
MX2011009807A true MX2011009807A (es) 2011-09-29

Family

ID=42226628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009807A MX2011009807A (es) 2009-03-19 2010-03-19 Compuestos.

Country Status (13)

Country Link
US (2) US20100317646A1 (es)
EP (1) EP2408772B1 (es)
JP (1) JP5732036B2 (es)
KR (1) KR101700229B1 (es)
CN (1) CN102428084B (es)
AU (1) AU2010224693B2 (es)
CA (1) CA2754605C (es)
CL (1) CL2011002267A1 (es)
IL (1) IL215147A0 (es)
MX (1) MX2011009807A (es)
PE (1) PE20120506A1 (es)
RU (1) RU2011142182A (es)
WO (1) WO2010106333A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715193A2 (pt) * 2006-08-16 2013-10-01 Hoffmann La Roche inibidores nço-nucleosÍdicos da transcriptase reversa
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
EP2632260A4 (en) * 2010-10-29 2015-06-17 Merck Sharp & Dohme ACTIVITY OF THE REPELLENT ENZYME KINASE RICH IN LEUCINE
EP2680695A4 (en) * 2011-02-28 2014-09-10 Merck Sharp & Dohme COMPOUNDS FOR INHIBITING THE REPEATING ACTIVITY OF A LEUKINARY KINASEENZYME
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
KR101649610B1 (ko) 2011-04-21 2016-08-19 오리제니스 게엠베하 키나아제 억제제로서의 헤테로사이클릭 화합물
KR20140041583A (ko) * 2011-05-23 2014-04-04 엘란 파마슈티컬스, 엘엘씨 Ｌｒｒｋ2 키나제 활성의 억제제
CN102558174B (zh) * 2011-08-23 2014-03-19 天津市斯芬克司药物研发有限公司 一种全新吡唑并[4,3-c]吡啶化合物的发明及其合成方法
PT2760453T (pt) * 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
TWI601726B (zh) * 2012-10-31 2017-10-11 拉夸里亞創藥股份有限公司 吡唑並吡啶衍生物作爲ｔｔｘ－ｓ阻斷劑
EA201500402A1 (ru) 2012-11-08 2016-05-31 Пфайзер Инк. Гетероароматические соединения в качестве лигандов допамина d1
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2968995B1 (en) * 2013-03-15 2018-05-09 Elan Pharmaceuticals LLC Inhibitors of lrrk2 kinase activity
TW201533043A (zh) * 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
AR096654A1 (es) * 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
EP3035800B1 (en) * 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
MD20160121A2 (ro) * 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
US10954240B2 (en) 2014-09-03 2021-03-23 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
EP3472171A4 (en) 2016-06-15 2019-12-18 Suzhou Yabao Pharmaceutical R&D Co., Ltd. SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
CN111566105A (zh) 2018-01-08 2020-08-21 豪夫迈·罗氏有限公司 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物
KR101990738B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
JP2023504623A (ja) * 2019-12-04 2023-02-06 アーカス バイオサイエンシーズ，インコーポレーテッド Ｈｉｆ－２アルファの阻害剤
CA3187145A1 (en) 2020-06-22 2021-12-30 F. Hoffmann-La Roche Ag Sulfone derivatives
AU2021338497A1 (en) * 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds
TW202342019A (zh) * 2022-02-25 2023-11-01 大陸商蘇州亞寶藥物研發有限公司 取代的稠環化合物及其藥物組合物、製備方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835144A (en) * 1972-06-16 1974-09-10 Squibb & Sons Inc Amino derivatives of (4,3-c pyrazolopyridine cabroxylic acids and esters
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2003241925A1 (en) * 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
JP2006501217A (ja) * 2002-08-12 2006-01-12 スージェン・インコーポレーテッド 新規キナーゼ阻害剤としての３−ピロリル−ピリドピラゾールおよび３−ピロリル−インダゾール
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
EP1653946A4 (en) * 2003-08-06 2007-04-04 Sugen Inc 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES GEOMETRICALLY LIMITED AS POWERFUL INHIBITORS OF PROTEIN KINASES
WO2005121094A1 (en) * 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
US20080081817A1 (en) * 2004-07-23 2008-04-03 Tanabe Seiyaku Co., Ltd. Nitrogenous Fused Bicyclic Compound
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2007089862A2 (en) * 2006-01-31 2007-08-09 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
US7879873B2 (en) * 2008-09-26 2011-02-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds

Also Published As

Publication number Publication date
CN102428084A (zh) 2012-04-25
JP2012520861A (ja) 2012-09-10
CN102428084B (zh) 2016-05-18
RU2011142182A (ru) 2013-04-27
WO2010106333A1 (en) 2010-09-23
CL2011002267A1 (es) 2012-05-11
KR20110128925A (ko) 2011-11-30
CA2754605C (en) 2018-04-17
PE20120506A1 (es) 2012-05-14
US20170320870A1 (en) 2017-11-09
AU2010224693B2 (en) 2016-07-28
JP5732036B2 (ja) 2015-06-10
AU2010224693A1 (en) 2011-09-15
CA2754605A1 (en) 2010-09-23
KR101700229B1 (ko) 2017-01-26
EP2408772A1 (en) 2012-01-25
US20100317646A1 (en) 2010-12-16
EP2408772B1 (en) 2015-07-01
IL215147A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
MX2011009807A (es) Compuestos.
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
NZ703162A (en) Heterocyclic modulators of lipid synthesis
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
TN2011000400A1 (en) Inhibitors of beta-secretase
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX344927B (es) Composición farmacéutica que contiene derivado de quinolina.
HK1166073A1 (en) Thienopyrimidinedione derivatives as trpa1 modulators
MX2013008255A (es) Derivados de aminodihidrotiazina fusionada.
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
AU2012248061C1 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
MX2012013274A (es) Novedosos derivados de la pirimidina.
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
EA201490722A1 (ru) ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5
IN2012DN02502A (es)
IN2014CN04449A (es)
GEP20135997B (en) Tricyclic indazole compound, method of their preparation and pharmaceutical composition containing thereof
UA104611C2 (en) Aroylamino- and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
EA201190269A1 (ru) 2'-фторарабинонуклеозиды и их применение

Legal Events

Date Code Title Description
FA Abandonment or withdrawal